Abstract
In this review, we focus on three key areas in acute myeloid leukemia (AML) developmental therapeutics: FLT3 inhibitors, IDH inhibitors, and drugs that may be particularly beneficial in secondary AML.
MeSH terms
-
Aminopyridines / therapeutic use
-
Humans
-
Isocitrate Dehydrogenase / antagonists & inhibitors*
-
Isocitrate Dehydrogenase / genetics
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / pathology
-
Molecular Targeted Therapy*
-
Mutation
-
Triazines / therapeutic use
-
fms-Like Tyrosine Kinase 3 / antagonists & inhibitors*
-
fms-Like Tyrosine Kinase 3 / genetics
Substances
-
Aminopyridines
-
Triazines
-
enasidenib
-
IDH2 protein, human
-
Isocitrate Dehydrogenase
-
IDH1 protein, human
-
FLT3 protein, human
-
fms-Like Tyrosine Kinase 3